TrialArthritis & rheumatology (Hoboken, N.J.)2021

Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus.

Matteo Cesaroni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.